RT @MasonIsraelPhD: FGFR2: The study that led to #pemigatinib approval in cholangiocarcinoma with #FGFR2 rearrangements just published. Thi…
RT @BenWestphalen: Just as a reminder. In the May 1st issue of @TheLancetOncol - Arndt Vogel & colleagues report the results from the phas…
RT @BenWestphalen: Just as a reminder. In the May 1st issue of @TheLancetOncol - Arndt Vogel & colleagues report the results from the phas…
RT @MasonIsraelPhD: FGFR2: The study that led to #pemigatinib approval in cholangiocarcinoma with #FGFR2 rearrangements just published. Thi…
RT @MasonIsraelPhD: FGFR2: The study that led to #pemigatinib approval in cholangiocarcinoma with #FGFR2 rearrangements just published. Thi…
RT @BenWestphalen: Just as a reminder. In the May 1st issue of @TheLancetOncol - Arndt Vogel & colleagues report the results from the phas…
This is a beautiful waterfall plot
FGFR2: The study that led to #pemigatinib approval in cholangiocarcinoma with #FGFR2 rearrangements just published. This is an important feather in the cap for #precisiononcology and I hope will be effective in other tumor types. @curecc
RT @BenWestphalen: Just as a reminder. In the May 1st issue of @TheLancetOncol - Arndt Vogel & colleagues report the results from the phas…
RT @BenWestphalen: Just as a reminder. In the May 1st issue of @TheLancetOncol - Arndt Vogel & colleagues report the results from the phas…
RT @BenWestphalen: Just as a reminder. In the May 1st issue of @TheLancetOncol - Arndt Vogel & colleagues report the results from the phas…
RT @BenWestphalen: Just as a reminder. In the May 1st issue of @TheLancetOncol - Arndt Vogel & colleagues report the results from the phas…
RT @BenWestphalen: Just as a reminder. In the May 1st issue of @TheLancetOncol - Arndt Vogel & colleagues report the results from the phas…
RT @BenWestphalen: Just as a reminder. In the May 1st issue of @TheLancetOncol - Arndt Vogel & colleagues report the results from the phas…
Just as a reminder. In the May 1st issue of @TheLancetOncol - Arndt Vogel & colleagues report the results from the phase 2 FIGHT2️⃣0️⃣2️⃣ trial. Impressive activity of pemigatinib in #cholangiocarcinoma w. FGFR2 fusios/rearrangements. #OncoAlert 🚨 ht
RT @kmody29: Pemigatinib #FGFR2 inhibition shows impressive results for 2nd line #cholangiocarcinoma 36%RR, 7.5m DOR. @GABOUALFA @Incyte @D…
RT @kmody29: Pemigatinib APPROVED! @Incyte @FDAOncology The first targeted therapy specifically approved for #cholangiocarcinoma @curecc
RT @kmody29: Pemigatinib APPROVED! @Incyte @FDAOncology The first targeted therapy specifically approved for #cholangiocarcinoma @curecc
RT @kmody29: Pemigatinib APPROVED! @Incyte @FDAOncology The first targeted therapy specifically approved for #cholangiocarcinoma @curecc
RT @kmody29: Pemigatinib APPROVED! @Incyte @FDAOncology The first targeted therapy specifically approved for #cholangiocarcinoma @curecc ht…
RT @kmody29: Pemigatinib APPROVED! @Incyte @FDAOncology The first targeted therapy specifically approved for #cholangiocarcinoma @curecc
Det är mycket välkomna framsteg för denna patientgrupp-från Memorial
Pemigatinib APPROVED! @Incyte @FDAOncology The first targeted therapy specifically approved for #cholangiocarcinoma @curecc
Congratulations to Dr. Abou-Alfa @GABOUALFA and colleagues on publication of pemigatinib in cholangiocarcinoma P2 FIGHT202 study. ORR 36% in FGFR2 fusions (but 0% in pt w/ other altercations), DOR ~8 mo. FDA approval poss, PDUFA 5/30 https://t.co/QWlXpJ9kt
エキパネでもよく名前を聞くFGFR1-3阻害剤ペミガチニブ、胆道癌P2(FIGHT-202試験)のESMO2019発表分?が出てた。FGFR2融合/再構成ではORR 35.5%、DCR 82%だけど他のFGF/FGFR変異には効果乏しい。FGFR2融合再構成かどうかで分けて考える必要ありそう。 /Lancet Oncol https://t.co/G0Ftssh0Mv
RT @kmody29: Pemigatinib #FGFR2 inhibition shows impressive results for 2nd line #cholangiocarcinoma 36%RR, 7.5m DOR. @GABOUALFA @Incyte @D…
RT @kmody29: Pemigatinib #FGFR2 inhibition shows impressive results for 2nd line #cholangiocarcinoma 36%RR, 7.5m DOR. @GABOUALFA @Incyte @D…
RT @kmody29: Pemigatinib #FGFR2 inhibition shows impressive results for 2nd line #cholangiocarcinoma 36%RR, 7.5m DOR. @GABOUALFA @Incyte @D…
Pemigatinib #FGFR2 inhibition shows impressive results for 2nd line #cholangiocarcinoma 36%RR, 7.5m DOR. @GABOUALFA @Incyte @DocCatenacci @MiteshBorad https://t.co/W4nM8Y6dew
RT @GABOUALFA: FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib fo…
RT @NatRevGastroHep: #GastroEdPick Phase 2 study: 146 patients with previously treated, locally advanced or metastatic #cholangiocarcinoma…
RT @TheLancetOncol: Online first: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcinoma…
RT @NatRevGastroHep: #GastroEdPick Phase 2 study: 146 patients with previously treated, locally advanced or metastatic #cholangiocarcinoma…
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
RT @NatRevGastroHep: #GastroEdPick Phase 2 study: 146 patients with previously treated, locally advanced or metastatic #cholangiocarcinoma…
#GastroEdPick Phase 2 study: 146 patients with previously treated, locally advanced or metastatic #cholangiocarcinoma were treated with pemigatinib (FGFR inhibitor). 35.5% of patients with FGFR2 alterations achieved an objective response @TheLancetOncol h
RT @Katsumata_Nori: ペニガチニブ、FGFR2融合遺伝子をもつ胆管がんに、35.5%の総効率を示した。胆管がんでのこの総効率はすごい。 The Lancet Oncology https://t.co/O0nyP7sUyx
RT @Katsumata_Nori: ペニガチニブ、FGFR2融合遺伝子をもつ胆管がんに、35.5%の総効率を示した。胆管がんでのこの総効率はすごい。 The Lancet Oncology https://t.co/O0nyP7sUyx
RT @Katsumata_Nori: ペニガチニブ、FGFR2融合遺伝子をもつ胆管がんに、35.5%の総効率を示した。胆管がんでのこの総効率はすごい。 The Lancet Oncology https://t.co/O0nyP7sUyx
RT @Katsumata_Nori: ペニガチニブ、FGFR2融合遺伝子をもつ胆管がんに、35.5%の総効率を示した。胆管がんでのこの総効率はすごい。 The Lancet Oncology https://t.co/O0nyP7sUyx
RT @Katsumata_Nori: ペニガチニブ、FGFR2融合遺伝子をもつ胆管がんに、35.5%の総効率を示した。胆管がんでのこの総効率はすごい。 The Lancet Oncology https://t.co/O0nyP7sUyx
RT @Katsumata_Nori: ペニガチニブ、FGFR2融合遺伝子をもつ胆管がんに、35.5%の総効率を示した。胆管がんでのこの総効率はすごい。 The Lancet Oncology https://t.co/O0nyP7sUyx
RT @Katsumata_Nori: ペニガチニブ、FGFR2融合遺伝子をもつ胆管がんに、35.5%の総効率を示した。胆管がんでのこの総効率はすごい。 The Lancet Oncology https://t.co/O0nyP7sUyx
おおっ!
RT @Katsumata_Nori: ペニガチニブ、FGFR2融合遺伝子をもつ胆管がんに、35.5%の総効率を示した。胆管がんでのこの総効率はすごい。 The Lancet Oncology https://t.co/O0nyP7sUyx
RT @Katsumata_Nori: ペニガチニブ、FGFR2融合遺伝子をもつ胆管がんに、35.5%の総効率を示した。胆管がんでのこの総効率はすごい。 The Lancet Oncology https://t.co/O0nyP7sUyx
ペニガチニブ、FGFR2融合遺伝子をもつ胆管がんに、35.5%の総効率を示した。胆管がんでのこの総効率はすごい。 The Lancet Oncology https://t.co/O0nyP7sUyx
RT @TheLancetOncol: Online first: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcinoma…
RT @TheLancetOncol: Online first: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcinoma…
RT @TheLancetOncol: Online first: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcinoma…
RT @TheLancetOncol: Online first: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcinoma…
RT @TheLancetOncol: Online first: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcinoma…
RT @TheLancetOncol: Online first: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcinoma…
RT @TheLancetOncol: Online first: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcinoma…
#pemigatinib entra en fase 2 de ensayo clínico para #colangiocarcinoma local o metastásico. #Cancer
RT @BenWestphalen: This is big news: Data of the FIGHT-202 trial in #cholangiocarcinoma out: Pemigatinib with an ORR of 3️⃣5️⃣%; DCR of…
RT @BenWestphalen: This is big news: Data of the FIGHT-202 trial in #cholangiocarcinoma out: Pemigatinib with an ORR of 3️⃣5️⃣%; DCR of…
RT @TheLancetOncol: Online first: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcinoma…
This is big news: Data of the FIGHT-202 trial in #cholangiocarcinoma out: Pemigatinib with an ORR of 3️⃣5️⃣%; DCR of 8️⃣2️⃣% , PFS 6️⃣.9️⃣ & OS 2️⃣1️⃣ months. All responses in in FGFR2-altered tumours. #OncoAlert @TheLancetOncol
RT @TheLancetOncol: Online first: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcinoma…
RT @TheLancetOncol: Online first: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcinoma…
RT @TheLancetOncol: Online first: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcinoma…
RT @TheLancetOncol: Online first: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcinoma…
Online first: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcinoma https://t.co/4TzHY5zdL7 https://t.co/IYFNb4Lnfg
RT @DenboJw: 35.5% response rate in previously treated locally advanced or metastatic #cholangiocarcinoma with FGFR fusions and rearrangeme…
RT @DenboJw: 35.5% response rate in previously treated locally advanced or metastatic #cholangiocarcinoma with FGFR fusions and rearrangeme…
RT @DenboJw: 35.5% response rate in previously treated locally advanced or metastatic #cholangiocarcinoma with FGFR fusions and rearrangeme…
RT @DenboJw: 35.5% response rate in previously treated locally advanced or metastatic #cholangiocarcinoma with FGFR fusions and rearrangeme…
RT @GABOUALFA: FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib fo…
RT @renumathyd: Promising phase 2 study for cholangiocarcinoma, a deadly cancer with very few treatment options. Data support the therapeu…
日本人に多い胆管癌に対し、インサイト(Nasdaq:INCY)社のペミガチニブという薬が効いた(LANCET oncol) Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study - The Lancet Oncology https://t.co/zMgGVeDOVx
RT @miyatamitsuru: 新しい分子標的FGFR2に対する分子標的薬の治験で有望な成績。 https://t.co/w1GXoNuAES
RT @miyatamitsuru: 新しい分子標的FGFR2に対する分子標的薬の治験で有望な成績。 https://t.co/w1GXoNuAES
新しい分子標的FGFR2に対する分子標的薬の治験で有望な成績。 https://t.co/w1GXoNuAES
RT @GABOUALFA: FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib fo…
RT @DenboJw: 35.5% response rate in previously treated locally advanced or metastatic #cholangiocarcinoma with FGFR fusions and rearrangeme…
RT @DenboJw: 35.5% response rate in previously treated locally advanced or metastatic #cholangiocarcinoma with FGFR fusions and rearrangeme…
RT @GABOUALFA: FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib fo…
RT @GABOUALFA: FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib fo…
RT @GABOUALFA: FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib fo…
RT @GABOUALFA: FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib fo…
RT @CoulouarnC: Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 s…
RT @GABOUALFA: FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib fo…
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study https://t.co/AUmrzDMLv0
RT @GABOUALFA: FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib fo…
RT @Alexfornergon: Hopes in the ongoing phase 3 trial FIGHT-402 https://t.co/3eQlu4uNhi
RT @Alexfornergon: Hopes in the ongoing phase 3 trial FIGHT-402 https://t.co/3eQlu4uNhi
Hopes in the ongoing phase 3 trial FIGHT-402 https://t.co/3eQlu4uNhi
RT @GABOUALFA: FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib fo…
RT @GABOUALFA: FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib fo…
35.5% response rate in previously treated locally advanced or metastatic #cholangiocarcinoma with FGFR fusions and rearrangements treated with Pemigatinib. @CCA_Alliance @curecc @AHPBA @SocSurgOnc @MoffittNews @MHepatobiliary @TheLancetOncol @TheLancet htt
RT @renumathyd: Promising phase 2 study for cholangiocarcinoma, a deadly cancer with very few treatment options. Data support the therapeu…
RT @CoulouarnC: Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 s…
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study https://t.co/G0tHJXNWhT
RT @GABOUALFA: FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib fo…
RT @GABOUALFA: FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib fo…
RT @GABOUALFA: FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib fo…
RT @GABOUALFA: FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib fo…
RT @GABOUALFA: FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib fo…
RT @GABOUALFA: FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib fo…